Effects of Bronchial Thermoplasty and Cryoablation on Airway Smooth Muscle
Bronchial asthma is a chronic inflammatory disease of the airways, characterized by airway hyperresponsiveness and remodeling. Among the 300 million asthma patients worldwide, refractory asthma accounts for 17.4% of cases. Despite advancements in biologic therapies targeting specific inflammatory pathways, a significant proportion of patients remain poorly controlled. Bronchial thermoplasty (BT) emerged as a therapeutic option for severe asthma, approved by the FDA in 2010. However, concerns regarding post-procedural complications such as bronchiectasis and bronchial scar formation have prompted exploration of alternative techniques. Cryoballoon ablation (CBA) has shown promise in various medical applications but had not been previously investigated for airway remodeling in asthma.
This study aimed to compare the effects of BT and CBA on airway smooth muscle (ASM) in a canine model, evaluating both short-term and long-term outcomes. The research was conducted using eight healthy male beagle dogs, with a comprehensive experimental design that included preliminary and subsequent experiments.
In the preliminary experiment, researchers tested different treatment durations for CBA (7 seconds and 30 seconds) to determine the optimal protocol. The results showed that while both durations effectively reduced ASM thickness, the 30-second treatment caused significant mucosal damage and inflammation without additional benefit. Consequently, the 7-second protocol was selected for subsequent experiments.
The subsequent experiments compared BT and CBA treatments in different bronchial segments, with evaluations at 1 month and 6 months post-treatment. Histological assessments included hematoxylin-eosin staining, Masson trichrome staining, and immunohistochemical staining for M3 receptor expression.
The key findings revealed that both BT and CBA significantly reduced ASM thickness compared to untreated controls. At 1 month post-treatment, CBA showed a more pronounced reduction in ASM thickness (4.81 ± 4.44 mm) compared to BT (13.41 ± 4.40 mm). However, by 6 months, the effects of both treatments were comparable (BT: 9.92 ± 4.42 mm; CBA: 7.41 ± 7.20 mm). This suggests that while CBA has a faster onset of action, both techniques achieve similar long-term results.
The study also examined the effects on collagen fiber synthesis. CBA treatment resulted in significantly higher collagen fiber synthesis compared to both BT and untreated controls at 1 month post-treatment. This indicates that the ablated ASM is replaced by fibrous tissue, potentially contributing to the long-term maintenance of airway patency.
A particularly interesting aspect of the research was the investigation of M3 receptor expression in ASM. The muscarinic M3 receptor plays a crucial role in bronchoconstriction and airway remodeling. Both BT and CBA significantly reduced M3 receptor expression, with CBA showing an earlier effect (1 month post-treatment) compared to BT (6 months post-treatment). This suggests that both techniques may modulate neural mechanisms involved in airway hyperresponsiveness.
The safety profile of both procedures was also assessed. While BT caused mild edema and capillary congestion, CBA resulted in more pronounced mucosal edema and red blood cell infiltration immediately post-treatment. However, these effects resolved by 1 month, and no significant complications were observed in either group.
The mechanisms underlying the effects of BT and CBA were discussed in detail. BT works through radiofrequency energy delivery, causing coagulative necrosis of ASM cells. CBA, on the other hand, induces cell death through ice crystal formation, cell dehydration, and electrolyte concentration changes. The study highlighted that CBA’s advantage lies in its ability to achieve effective ASM ablation without scar formation, potentially reducing long-term complications.
The implications of these findings are significant for the treatment of severe asthma. The demonstration that CBA can achieve comparable results to BT, with a faster onset of action and potentially fewer complications, opens new possibilities for interventional asthma management. The reduction in M3 receptor expression suggests that both techniques may address not only the structural aspects of airway remodeling but also the neural mechanisms contributing to airway hyperresponsiveness.
However, the study also acknowledged limitations. The experiments were conducted on healthy canine models rather than asthma models, and the observation period was limited to 6 months. Future research should address these limitations by using appropriate disease models and extending the follow-up period to assess long-term efficacy and safety.
In conclusion, this comprehensive comparison of BT and CBA provides valuable insights into their effects on ASM. The findings suggest that CBA is a promising alternative to BT, with equivalent long-term efficacy and potentially favorable safety profile. The demonstration of neural mechanism involvement through M3 receptor modulation adds an important dimension to our understanding of these interventions. These results pave the way for further clinical investigations and potential application of CBA in the management of severe asthma.
doi.org/10.1097/CM9.0000000000001681
Was this helpful?
0 / 0